|1.||Grossbard, Elliott B: 8 articles (07/2013 - 04/2005)|
|2.||Tsokos, George C: 7 articles (07/2015 - 09/2007)|
|3.||Wang, Lei: 6 articles (04/2015 - 08/2003)|
|4.||Weinblatt, Michael E: 6 articles (12/2014 - 11/2008)|
|5.||Dai, Jia Le: 6 articles (03/2014 - 08/2003)|
|6.||Kavanaugh, Arthur: 5 articles (12/2014 - 11/2008)|
|7.||Genovese, Mark C: 4 articles (12/2014 - 09/2010)|
|8.||Yuan, Yunfei: 4 articles (03/2014 - 02/2005)|
|9.||Zirlik, Katja: 4 articles (02/2014 - 07/2009)|
|10.||Ruland, Jürgen: 4 articles (02/2014 - 08/2009)|
03/01/2012 - "The compounds are Syk kinase inhibitors useful in the treatment of allergic and inflammatory diseases and cancer. "
07/27/2010 - "Drug targeting of C35 or Syk kinase might be helpful in treating a subset of patients with HER2-amplified breast cancers."
11/01/2014 - "To study the effect of gene transfection of full length spleen tyrosine kinase (Syk (L)) on the biological behavior of malignant cancer cells. "
12/01/2015 - "This disease is associated with epigenetic deregulation of several cancer pathways including upregulation of the proto-oncogene spleen tyrosine kinase (SYK). "
01/01/2013 - "The nonreceptor Syk kinase is detected in epithelial cells, where it acts as a tumor suppressor, in addition to its well-established role in immunoreceptor-based signal transduction in hematopoietic cells. "
|2.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
06/03/2010 - "Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia."
04/09/2015 - "An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia."
12/01/2014 - "Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia."
02/28/2014 - "A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor."
07/01/2012 - "Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration."
|3.||Retinoblastoma (Glioblastoma, Retinal)
11/01/2014 - "Pharmacokinetics and efficacy of the spleen tyrosine kinase inhibitor r406 after ocular delivery for retinoblastoma."
11/01/2014 - "Recent studies characterizing the genomic and epigenomic landscape of retinoblastoma identified spleen tyrosine kinase (SYK) as a promising candidate for targeted therapy. "
01/01/2012 - "However, the recent discovery of aberrant expression of the gene encoding spleen tyrosine kinase (SYK) subsequent to widespread methylation abnormalities in retinoblastoma suggests a potential new therapy for the disease. "
04/24/2012 - "Key mechanisms underlying the effect of PPARγ in HCC include upregulation of cell adhesion genes, E-cadherin and SYK (spleen tyrosine kinase), extracellular matrix regulator tissue inhibitors of metalloproteinase (TIMP) 3, tumour suppressor gene retinoblastoma 1, and downregulation of pro-metastatic genes MMP9 (matrix metallopeptidase 9), MMP13, HPSE (heparanase), and Hepatocyte growth factor (HGF). "
|4.||Vascular System Injuries
11/03/2011 - "Here, as one remarkable example, studies using a novel and highly selective pharmacologic inhibitor of the spleen tyrosine kinase Syk [PRT060318; 2-((1R,2S)-2-aminocyclohexylamino)-4-(m-tolylamino)pyrimidine-5-carboxamide] coupled with genetic experiments, demonstrate that Syk inhibition ameliorates both the acute and chronic responses to vascular injury without affecting hemostasis. "
|2.||Acetic Acid (Vinegar)
|4.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|8.||Epidermal Growth Factor Receptor (EGF Receptor)
|10.||Vascular Endothelial Growth Factor C
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)